HC Wainwright Comments on Fennec Pharmaceuticals Inc's FY2025 Earnings (NASDAQ:FENC)

Fennec Pharmaceuticals Inc (NASDAQ:FENC - Free Report) - Analysts at HC Wainwright upped their FY2025 earnings estimates for shares of Fennec Pharmaceuticals in a research note issued on Wednesday, May 15th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of $0.86 per share for the year, up from their previous forecast of $0.78. HC Wainwright currently has a "Buy" rating and a $15.00 price target on the stock. The consensus estimate for Fennec Pharmaceuticals' current full-year earnings is $0.51 per share. HC Wainwright also issued estimates for Fennec Pharmaceuticals' Q4 2025 earnings at $0.34 EPS.

A number of other equities research analysts also recently commented on FENC. Craig Hallum decreased their target price on Fennec Pharmaceuticals from $20.00 to $17.00 and set a "buy" rating for the company in a report on Wednesday. Wedbush reaffirmed an "outperform" rating and issued a $16.00 price objective on shares of Fennec Pharmaceuticals in a report on Tuesday.

Fennec Pharmaceuticals Price Performance

FENC traded up $0.14 on Thursday, reaching $7.12. 361,404 shares of the stock were exchanged, compared to its average volume of 130,973. The company's 50-day moving average price is $9.92 and its 200 day moving average price is $9.62. The firm has a market capitalization of $194.52 million, a PE ratio of -11.67 and a beta of 0.45. Fennec Pharmaceuticals has a fifty-two week low of $6.30 and a fifty-two week high of $11.92.

Fennec Pharmaceuticals (NASDAQ:FENC - Get Free Report) last posted its quarterly earnings results on Tuesday, May 14th. The company reported $0.41 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.49 by ($0.08). The business had revenue of $25.38 million for the quarter, compared to analyst estimates of $10.46 million. During the same period in the prior year, the company posted ($0.23) earnings per share.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. AIGH Capital Management LLC grew its holdings in shares of Fennec Pharmaceuticals by 6.9% during the third quarter. AIGH Capital Management LLC now owns 373,526 shares of the company's stock worth $2,805,000 after buying an additional 24,069 shares in the last quarter. Allspring Global Investments Holdings LLC acquired a new stake in Fennec Pharmaceuticals in the 3rd quarter valued at about $50,000. Eudaimonia Advisors LLC lifted its stake in Fennec Pharmaceuticals by 90.8% in the 4th quarter. Eudaimonia Advisors LLC now owns 32,686 shares of the company's stock worth $367,000 after purchasing an additional 15,556 shares in the last quarter. Gendell Jeffrey L boosted its holdings in shares of Fennec Pharmaceuticals by 0.9% during the 3rd quarter. Gendell Jeffrey L now owns 285,992 shares of the company's stock worth $2,148,000 after purchasing an additional 2,579 shares during the last quarter. Finally, Hartford Financial Management Inc. grew its position in shares of Fennec Pharmaceuticals by 4.4% in the fourth quarter. Hartford Financial Management Inc. now owns 47,348 shares of the company's stock valued at $531,000 after purchasing an additional 2,000 shares in the last quarter. 55.51% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Fennec Pharmaceuticals

In other Fennec Pharmaceuticals news, CFO Robert Andrade sold 13,975 shares of the company's stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $11.00, for a total value of $153,725.00. Following the sale, the chief financial officer now owns 105,746 shares in the company, valued at approximately $1,163,206. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, CEO Rosty Raykov sold 44,300 shares of the company's stock in a transaction dated Friday, April 5th. The shares were sold at an average price of $10.75, for a total transaction of $476,225.00. Following the completion of the transaction, the chief executive officer now owns 187,471 shares in the company, valued at approximately $2,015,313.25. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Robert Andrade sold 13,975 shares of the firm's stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $11.00, for a total value of $153,725.00. Following the completion of the transaction, the chief financial officer now owns 105,746 shares in the company, valued at approximately $1,163,206. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 193,093 shares of company stock worth $1,984,921. 11.25% of the stock is owned by corporate insiders.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.